Tullis Health Investors

Exagen Inc. is a commercial-stage diagnostics company focused on developing and commercializing innovative testing products for autoimmune and autoimmune-related diseases. Headquartered in Vista, California, Exagen utilizes its proprietary Cell-Bound Complement Activation Products technology to enhance diagnostic care for conditions like systemic lupus erythematosus and rheumatoid arthritis. The company offers a diverse portfolio of testing products under its AVISE brand, including AVISE CTD for differential diagnosis of connective tissue diseases, AVISE Lupus for monitoring complement system activation, and multiple panels for assessing various autoimmune markers. These products facilitate timely diagnosis and effective therapeutic interventions, enabling rheumatologists to improve patient care. Since its founding in 2002, Exagen has remained committed to addressing the needs of patients suffering from chronic autoimmune diseases.

TriSalus Life Sciences is a biotechnology company based in Westminster, Colorado, founded in 2009. The company specializes in developing innovative precision infusion systems for the interventional radiology market, focusing on the treatment of liver and pancreatic cancers. TriSalus's flagship products include the Surefire precision infusion systems, which utilize a unique expandable tip design to deliver embolic agents precisely while minimizing damage to healthy tissue. The company also offers Pressure Enabled Drug Delivery (PEDD) systems and is developing an investigational agent, nelitolimod, aimed at enhancing immune responses in cancer therapies. Additionally, TriSalus is advancing its TriNav therapy delivery device, which incorporates SmartValve technology for improved drug delivery.

CareSync is a leading provider of software and services focused on chronic disease management. The company integrates technology with 24/7 nursing services to enhance care coordination among patients, families, caregivers, and healthcare providers. CareSync offers turnkey Chronic Care Management services and a software-only solution that enables healthcare practices of all sizes to comply with billing requirements for chronic care services. Its certified technology facilitates meeting Meaningful Use standards for data exchange, messaging, and timely access to health information. By centralizing health records from multiple providers in a secure location and employing medical records retrieval specialists, CareSync ensures that caregivers and providers can quickly access and share relevant patient information. This comprehensive approach empowers patients by providing them with access to their health information, actionable goals, and care plans, ultimately leading to more productive medical appointments and improved health outcomes.

OrthoSensor, Inc. is a medical device company based in Dania Beach, Florida, specializing in orthopedic devices and data services for surgeons and hospitals. Established in 2007, OrthoSensor develops innovative sensor-assisted technologies aimed at enhancing orthopedic procedures. Its flagship product, VERASENSE, is a disposable instrument used in total knee arthroplasty that provides real-time, evidence-based data to assist surgeons in making informed decisions regarding soft tissue balance and implant positioning during surgery. Additionally, the company offers OrthoLogIQ, a cloud-based system that integrates data from VERASENSE with patient demographics and reported outcomes. OrthoSensor's focus on using advanced sensors and communications technologies, alongside its software solutions, seeks to improve patient outcomes and potentially lower the costs associated with treating musculoskeletal diseases. The company markets its products through direct sales representatives across the United States and maintains partnerships to enhance its innovative offerings.

CareSync is a leading provider of software and services focused on chronic disease management. The company integrates technology with 24/7 nursing services to enhance care coordination among patients, families, caregivers, and healthcare providers. CareSync offers turnkey Chronic Care Management services and a software-only solution that enables healthcare practices of all sizes to comply with billing requirements for chronic care services. Its certified technology facilitates meeting Meaningful Use standards for data exchange, messaging, and timely access to health information. By centralizing health records from multiple providers in a secure location and employing medical records retrieval specialists, CareSync ensures that caregivers and providers can quickly access and share relevant patient information. This comprehensive approach empowers patients by providing them with access to their health information, actionable goals, and care plans, ultimately leading to more productive medical appointments and improved health outcomes.

Exagen Inc. is a commercial-stage diagnostics company focused on developing and commercializing innovative testing products for autoimmune and autoimmune-related diseases. Headquartered in Vista, California, Exagen utilizes its proprietary Cell-Bound Complement Activation Products technology to enhance diagnostic care for conditions like systemic lupus erythematosus and rheumatoid arthritis. The company offers a diverse portfolio of testing products under its AVISE brand, including AVISE CTD for differential diagnosis of connective tissue diseases, AVISE Lupus for monitoring complement system activation, and multiple panels for assessing various autoimmune markers. These products facilitate timely diagnosis and effective therapeutic interventions, enabling rheumatologists to improve patient care. Since its founding in 2002, Exagen has remained committed to addressing the needs of patients suffering from chronic autoimmune diseases.

Exagen Inc. is a commercial-stage diagnostics company focused on developing and commercializing innovative testing products for autoimmune and autoimmune-related diseases. Headquartered in Vista, California, Exagen utilizes its proprietary Cell-Bound Complement Activation Products technology to enhance diagnostic care for conditions like systemic lupus erythematosus and rheumatoid arthritis. The company offers a diverse portfolio of testing products under its AVISE brand, including AVISE CTD for differential diagnosis of connective tissue diseases, AVISE Lupus for monitoring complement system activation, and multiple panels for assessing various autoimmune markers. These products facilitate timely diagnosis and effective therapeutic interventions, enabling rheumatologists to improve patient care. Since its founding in 2002, Exagen has remained committed to addressing the needs of patients suffering from chronic autoimmune diseases.

Exagen Inc. is a commercial-stage diagnostics company focused on developing and commercializing innovative testing products for autoimmune and autoimmune-related diseases. Headquartered in Vista, California, Exagen utilizes its proprietary Cell-Bound Complement Activation Products technology to enhance diagnostic care for conditions like systemic lupus erythematosus and rheumatoid arthritis. The company offers a diverse portfolio of testing products under its AVISE brand, including AVISE CTD for differential diagnosis of connective tissue diseases, AVISE Lupus for monitoring complement system activation, and multiple panels for assessing various autoimmune markers. These products facilitate timely diagnosis and effective therapeutic interventions, enabling rheumatologists to improve patient care. Since its founding in 2002, Exagen has remained committed to addressing the needs of patients suffering from chronic autoimmune diseases.

Estech, founded in 1996 by Arthur and Raymond Bertolero, is a privately held medical device manufacturing and distribution company based in San Ramon, California. The company specializes in developing and marketing medical devices and disposables for cardiac surgery, with a focus on least invasive products. Estech's global distribution network and commitment to innovation have attracted top professionals in the medical device industry. The company's success is attributed to the extensive experience and dedication of its team, which has enabled it to thrive in the competitive medical device market.

Exagen Inc. is a commercial-stage diagnostics company focused on developing and commercializing innovative testing products for autoimmune and autoimmune-related diseases. Headquartered in Vista, California, Exagen utilizes its proprietary Cell-Bound Complement Activation Products technology to enhance diagnostic care for conditions like systemic lupus erythematosus and rheumatoid arthritis. The company offers a diverse portfolio of testing products under its AVISE brand, including AVISE CTD for differential diagnosis of connective tissue diseases, AVISE Lupus for monitoring complement system activation, and multiple panels for assessing various autoimmune markers. These products facilitate timely diagnosis and effective therapeutic interventions, enabling rheumatologists to improve patient care. Since its founding in 2002, Exagen has remained committed to addressing the needs of patients suffering from chronic autoimmune diseases.

Exagen Inc. is a commercial-stage diagnostics company focused on developing and commercializing innovative testing products for autoimmune and autoimmune-related diseases. Headquartered in Vista, California, Exagen utilizes its proprietary Cell-Bound Complement Activation Products technology to enhance diagnostic care for conditions like systemic lupus erythematosus and rheumatoid arthritis. The company offers a diverse portfolio of testing products under its AVISE brand, including AVISE CTD for differential diagnosis of connective tissue diseases, AVISE Lupus for monitoring complement system activation, and multiple panels for assessing various autoimmune markers. These products facilitate timely diagnosis and effective therapeutic interventions, enabling rheumatologists to improve patient care. Since its founding in 2002, Exagen has remained committed to addressing the needs of patients suffering from chronic autoimmune diseases.

Exagen Inc. is a commercial-stage diagnostics company focused on developing and commercializing innovative testing products for autoimmune and autoimmune-related diseases. Headquartered in Vista, California, Exagen utilizes its proprietary Cell-Bound Complement Activation Products technology to enhance diagnostic care for conditions like systemic lupus erythematosus and rheumatoid arthritis. The company offers a diverse portfolio of testing products under its AVISE brand, including AVISE CTD for differential diagnosis of connective tissue diseases, AVISE Lupus for monitoring complement system activation, and multiple panels for assessing various autoimmune markers. These products facilitate timely diagnosis and effective therapeutic interventions, enabling rheumatologists to improve patient care. Since its founding in 2002, Exagen has remained committed to addressing the needs of patients suffering from chronic autoimmune diseases.

Exagen Inc. is a commercial-stage diagnostics company focused on developing and commercializing innovative testing products for autoimmune and autoimmune-related diseases. Headquartered in Vista, California, Exagen utilizes its proprietary Cell-Bound Complement Activation Products technology to enhance diagnostic care for conditions like systemic lupus erythematosus and rheumatoid arthritis. The company offers a diverse portfolio of testing products under its AVISE brand, including AVISE CTD for differential diagnosis of connective tissue diseases, AVISE Lupus for monitoring complement system activation, and multiple panels for assessing various autoimmune markers. These products facilitate timely diagnosis and effective therapeutic interventions, enabling rheumatologists to improve patient care. Since its founding in 2002, Exagen has remained committed to addressing the needs of patients suffering from chronic autoimmune diseases.

Estech, founded in 1996 by Arthur and Raymond Bertolero, is a privately held medical device manufacturing and distribution company based in San Ramon, California. The company specializes in developing and marketing medical devices and disposables for cardiac surgery, with a focus on least invasive products. Estech's global distribution network and commitment to innovation have attracted top professionals in the medical device industry. The company's success is attributed to the extensive experience and dedication of its team, which has enabled it to thrive in the competitive medical device market.

BioBehavioral Diagnostics is a manufacturer of diagnostic systems designed for the quantitative assessment of behavioral and neurobiological disorders, specifically focusing on attention-deficit/hyperactivity disorder (ADHD). The company develops and markets the Quotient ADHD System, a proprietary platform that objectively measures specific behaviors related to brain function and inhibitory control. This system collects data on an individual's ability to remain still, inhibit impulsivity, and respond accurately to visual stimuli presented on a computer screen. By providing physicians, parents, and patients with high-value information, BioBehavioral Diagnostics aims to guide personalized treatment strategies and improve the quality of life for those affected by ADHD.

Synageva BioPharma is a biopharmaceutical company that specializes in the development and commercialization of innovative protein therapeutics, particularly targeting rare diseases. Utilizing its proprietary Synageva Expression Platform, the company aims to create next-generation and follow-on therapies that address unmet medical needs. By focusing on rare diseases, Synageva seeks to improve treatment options and outcomes for patients with these conditions, thereby positioning itself as a key player in the biopharmaceutical sector.

Coherex Medical, Inc. is a medical device company based in Salt Lake City, Utah, focused on developing and marketing catheter-based technologies for the treatment of structural heart defects. Founded in 2003 as Proximare, Inc., the company rebranded in 2006 to its current name. Coherex Medical specializes in devices designed for patients with atrial fibrillation, aiming to reduce the risk of stroke. Its product offerings include a patent foramen ovale (PFO) closure system that promotes tissue in-growth for long-term closure and a WaveCrest device intended to close the left atrial appendage, enhancing the safety and simplicity of implant procedures. The company serves both domestic and international markets, providing innovative solutions for addressing structural heart disease.

Vidacare Corporation is a medical device company based in San Antonio, Texas, specializing in intraosseous access technology. Founded in 2001, the company develops, manufactures, and markets devices designed for diagnostic, monitoring, and therapeutic applications, particularly in emergency situations where traditional vascular access is challenging. Its primary product, the EZ-IO Product System, enables controlled vascular access through the intraosseous route, utilizing a power driver that drills through bone to secure placement. Additionally, Vidacare offers a suite of products for hematology and oncology, including tools for bone marrow aspiration and biopsy. Its offerings are utilized in various settings, including pre-hospital care, emergency response, and military applications, addressing critical needs in bone and blood-related medicine.

Synageva BioPharma is a biopharmaceutical company that specializes in the development and commercialization of innovative protein therapeutics, particularly targeting rare diseases. Utilizing its proprietary Synageva Expression Platform, the company aims to create next-generation and follow-on therapies that address unmet medical needs. By focusing on rare diseases, Synageva seeks to improve treatment options and outcomes for patients with these conditions, thereby positioning itself as a key player in the biopharmaceutical sector.

Ikano Therapeutics a specialty pharmaceutical company, focuses on developing nasal spray drug products.

Atritech is a private medical technology company based in Minneapolis, Minnesota, founded in 2000. The company specializes in developing minimally invasive technologies aimed at preventing strokes related to atrial fibrillation. Their flagship product, the WATCHMAN Left Atrial Appendage Closure Technology, is designed to offer a permanent alternative to long-term anticoagulation therapy for patients with non-valvular atrial fibrillation who are at risk of stroke. The device works by closing off the left atrial appendage, preventing harmful blood clots from entering the bloodstream and causing strokes or other complications. The WATCHMAN Device has been CE Marked and is available in many markets outside the United States, while it is currently under investigation in the U.S.

Aldagen is a biopharmaceutical company focused on developing proprietary regenerative cell therapies to address significant unmet medical needs. The company has four product candidates in clinical trials, with ALD-101 being the most advanced. Aldagen is currently conducting a pivotal Phase 3 clinical trial of ALD-101 to enhance umbilical cord blood transplants for treating inherited metabolic diseases in pediatric patients. Additionally, the company is involved in or supporting Phase 1 or Phase 1/2 clinical trials for three other product candidates: ALD-151 for improving cord blood transplants used in leukemia treatment; ALD-301 for critical limb ischemia; and ALD-201 for ischemic heart failure. Aldagen's work also includes developing therapies to address cardiovascular disease.

Atritech is a private medical technology company based in Minneapolis, Minnesota, founded in 2000. The company specializes in developing minimally invasive technologies aimed at preventing strokes related to atrial fibrillation. Their flagship product, the WATCHMAN Left Atrial Appendage Closure Technology, is designed to offer a permanent alternative to long-term anticoagulation therapy for patients with non-valvular atrial fibrillation who are at risk of stroke. The device works by closing off the left atrial appendage, preventing harmful blood clots from entering the bloodstream and causing strokes or other complications. The WATCHMAN Device has been CE Marked and is available in many markets outside the United States, while it is currently under investigation in the U.S.

Aldagen is a biopharmaceutical company focused on developing proprietary regenerative cell therapies to address significant unmet medical needs. The company has four product candidates in clinical trials, with ALD-101 being the most advanced. Aldagen is currently conducting a pivotal Phase 3 clinical trial of ALD-101 to enhance umbilical cord blood transplants for treating inherited metabolic diseases in pediatric patients. Additionally, the company is involved in or supporting Phase 1 or Phase 1/2 clinical trials for three other product candidates: ALD-151 for improving cord blood transplants used in leukemia treatment; ALD-301 for critical limb ischemia; and ALD-201 for ischemic heart failure. Aldagen's work also includes developing therapies to address cardiovascular disease.

Impulse Monitoring is a provider of intra-operative neurophysiological monitoring solutions, headquartered in Columbia, Maryland. The company specializes in offering monitoring services during spinal, nerve, and brain-related surgeries, as well as other medical procedures such as orthopedic, vascular, cardiac, and otolaryngology surgeries. Its primary product, IONM, delivers critical insights into the nervous system, helping surgeons identify potential risks and make informed decisions during operations. By providing real-time information and alerts regarding the spinal cord and neural structures, Impulse Monitoring enhances surgical safety and supports improved patient outcomes across various healthcare settings.

BioBehavioral Diagnostics is a manufacturer of diagnostic systems designed for the quantitative assessment of behavioral and neurobiological disorders, specifically focusing on attention-deficit/hyperactivity disorder (ADHD). The company develops and markets the Quotient ADHD System, a proprietary platform that objectively measures specific behaviors related to brain function and inhibitory control. This system collects data on an individual's ability to remain still, inhibit impulsivity, and respond accurately to visual stimuli presented on a computer screen. By providing physicians, parents, and patients with high-value information, BioBehavioral Diagnostics aims to guide personalized treatment strategies and improve the quality of life for those affected by ADHD.

Adiana, Inc. is a company based in Redwood City, California, founded in 1997, that focuses on the development and testing of transcervical sterilization systems for permanent birth control. The company's main product, Complete TCS, comprises a radiofrequency generator, delivery catheter, and implantable matrix, designed to occlude the fallopian tubes and prevent pregnancy. Adiana aims to provide a novel, non-incisional alternative to traditional tubal ligation, offering women a solution that minimizes the side effects and complications associated with other contraceptive methods. As of 2007, Adiana operates as a subsidiary of CYTYC Corp.

Exagen Inc. is a commercial-stage diagnostics company focused on developing and commercializing innovative testing products for autoimmune and autoimmune-related diseases. Headquartered in Vista, California, Exagen utilizes its proprietary Cell-Bound Complement Activation Products technology to enhance diagnostic care for conditions like systemic lupus erythematosus and rheumatoid arthritis. The company offers a diverse portfolio of testing products under its AVISE brand, including AVISE CTD for differential diagnosis of connective tissue diseases, AVISE Lupus for monitoring complement system activation, and multiple panels for assessing various autoimmune markers. These products facilitate timely diagnosis and effective therapeutic interventions, enabling rheumatologists to improve patient care. Since its founding in 2002, Exagen has remained committed to addressing the needs of patients suffering from chronic autoimmune diseases.

Myocor is a medical company based in Minnesota, founded in 1996, that specializes in developing and distributing therapeutic products aimed at treating mitral regurgitation and heart failure. The company focuses on creating medical devices that alter the physiology of heart failure, ultimately enhancing clinical outcomes for patients with late-stage heart conditions. One of its notable innovations is the Coapsys device, which utilizes pads and a tensioned string to reshape an enlarged heart and improve the functionality of a leaky mitral valve. By providing these advanced technologies, Myocor seeks to improve cardiac function and offer effective solutions for individuals suffering from heart-related ailments.

Valeo Medical, Inc., a life sciences company, develops a non-invasive diagnostic blood test for endometriosis. The company was founded in 2003 and is based in Burlington, Massachusetts. Valeo raised money as part of the Discovery Life Sciences fund which was partly funded by the Nashville Capital Network.

BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.

TransMolecular, Inc. is a neuroscience biotechnology company dedicated to discovering, developing, and commercializing innovative drugs aimed at diagnosing and treating central nervous system diseases, particularly focusing on cancer and pain management. Founded in July 1996 and based in Birmingham, Alabama, the company has established robust technology platforms that enhance its product discovery and development pipeline. TransMolecular has received significant funding through private placements and Small Business Incentive Research grants from the National Institutes of Health, totaling $1 million for its cancer and pain programs. The company holds over 25 patents and has exclusive licensing agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its specialized technologies. Its management team, boasting more than 75 years of combined experience in healthcare, pharmaceutical development, and research, is committed to advancing safe and effective therapeutic solutions for patients with limited treatment options.

Exagen Inc. is a commercial-stage diagnostics company focused on developing and commercializing innovative testing products for autoimmune and autoimmune-related diseases. Headquartered in Vista, California, Exagen utilizes its proprietary Cell-Bound Complement Activation Products technology to enhance diagnostic care for conditions like systemic lupus erythematosus and rheumatoid arthritis. The company offers a diverse portfolio of testing products under its AVISE brand, including AVISE CTD for differential diagnosis of connective tissue diseases, AVISE Lupus for monitoring complement system activation, and multiple panels for assessing various autoimmune markers. These products facilitate timely diagnosis and effective therapeutic interventions, enabling rheumatologists to improve patient care. Since its founding in 2002, Exagen has remained committed to addressing the needs of patients suffering from chronic autoimmune diseases.

Valeo Medical, Inc., a life sciences company, develops a non-invasive diagnostic blood test for endometriosis. The company was founded in 2003 and is based in Burlington, Massachusetts. Valeo raised money as part of the Discovery Life Sciences fund which was partly funded by the Nashville Capital Network.

BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.

TransMolecular, Inc. is a neuroscience biotechnology company dedicated to discovering, developing, and commercializing innovative drugs aimed at diagnosing and treating central nervous system diseases, particularly focusing on cancer and pain management. Founded in July 1996 and based in Birmingham, Alabama, the company has established robust technology platforms that enhance its product discovery and development pipeline. TransMolecular has received significant funding through private placements and Small Business Incentive Research grants from the National Institutes of Health, totaling $1 million for its cancer and pain programs. The company holds over 25 patents and has exclusive licensing agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its specialized technologies. Its management team, boasting more than 75 years of combined experience in healthcare, pharmaceutical development, and research, is committed to advancing safe and effective therapeutic solutions for patients with limited treatment options.

SupplyPro, Inc. is a manufacturer and marketer of inventory management solutions based in San Diego, California. Established in 1997, the company offers a diverse range of products designed to optimize inventory control in various environments, including manufacturing, maintenance, and office settings. Key offerings include SupplyAgent, a basic control system for materials; SupplyBay, tailored for harsh industrial conditions; and SupplyLocker, which manages consumables and tools. Additionally, SupplyPro provides advanced solutions such as SupplySystem, a modular inventory control system, and SupplyPro Virtual Inventory Management, which tracks products not physically present in devices. The company serves multiple industries, including automotive, aerospace, energy, and food and beverage, focusing on enhancing productivity while minimizing inventory costs through just-in-time inventory practices and automated replenishment features.

AmericasDoctor, a unique pharmaceutical services company, combines and integrates leading physician researchers, strategic marketing and consumer outreach capabilities, distinguished hospitals and advanced Internet resources to assist the pharmaceutical industry in developing, positioning and promoting its products. AmericasDoctor was formed in January 2000 from a merger between Affiliated Research Centers (ARC) and AmericasDoctor.com. AmericasDoctor Research Services (formerly ARC) provides investigative site and patient recruitment capabilities through its 150 investigative sites operating in 37 states in the U.S. and five provinces in Canada. Currently, AmericasDoctor is conducting over 550 studies in urology, rheumatology, pulmonology and respiratory disease, endocrinology, cardiology, women’s health, gastroenterology and neuroscience. AmericasDoctor Web Services provides information to consumers in response to health information inquiries. It is the only medical/health Internet site to offer private, real-time, one-on-one chats with board-certified, board-eligible physicians 24 hours a day, seven days a week at no cost to the consumer. This site is sponsored by over 100 leading U.S. hospitals. AmericasDoctor supports the combined efforts of the medical community and pharmaceutical industry to improve the lives of people suffering from chronic illnesses. AmericasDoctor provides the vital link between the patient, the medical expert and the development of new therapies. To the consumer, this means enhanced lives, the empowerment to manage their medical situations and the possibility of improved treatment efficacy. For pharmaceutical companies, this means unique approaches in defining, developing and expediting new products and solutions. AmericasDoctor is a privately held company with a strategic vision to provide a new generation of pharmaceutical services integrating information, marketing and research resources to help create tomorrow’s medicine.

Centromine offers a browser-based, internet-accessed, enterprise-wide software applications and services for the health care market. Its applications allow behavioral health care programs and providers to manage the delivery and associated quality and cost of services completely over the internet.

TransMolecular, Inc. is a neuroscience biotechnology company dedicated to discovering, developing, and commercializing innovative drugs aimed at diagnosing and treating central nervous system diseases, particularly focusing on cancer and pain management. Founded in July 1996 and based in Birmingham, Alabama, the company has established robust technology platforms that enhance its product discovery and development pipeline. TransMolecular has received significant funding through private placements and Small Business Incentive Research grants from the National Institutes of Health, totaling $1 million for its cancer and pain programs. The company holds over 25 patents and has exclusive licensing agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its specialized technologies. Its management team, boasting more than 75 years of combined experience in healthcare, pharmaceutical development, and research, is committed to advancing safe and effective therapeutic solutions for patients with limited treatment options.